Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Orgenesis's Sloan Ratio for the quarter that ended in Mar. 2022 was 28.57%.
Warning Sign:
When Sloan Ratio (35.42)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2022, Orgenesis has a Sloan Ratio of 28.57%, indicating earnings are more likely to be made up of accruals.
Orgenesis Sloan Ratio % Historical Data
The historical data trend for Orgenesis's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Sloan Ratio %
-12.87
4.85
3.11
-34.05
35.42
Orgenesis Quarterly Data
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Sloan Ratio %
-2.70
24.67
23.70
35.42
28.57
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Sloan Ratio % Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Orgenesis's Sloan Ratio % falls into.
Orgenesis Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Orgenesis's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Orgenesis's Net Income for the trailing twelve months (TTM) ended in Mar. 2022 was -2.659 (Jun. 2021 ) + -10.159 (Sep. 2021 ) + -5.016 (Dec. 2021 ) + -4.009 (Mar. 2022 ) = $-21.84 Mil.
Orgenesis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2022 was -11.5 (Jun. 2021 ) + -8.355 (Sep. 2021 ) + -2.464 (Dec. 2021 ) + -2.792 (Mar. 2022 ) = $-25.11 Mil.
Orgenesis's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2022 was -1.023 (Jun. 2021 ) + -5.082 (Sep. 2021 ) + -5.74 (Dec. 2021 ) + -1.613 (Mar. 2022 ) = $-13.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2022, Orgenesis has a Sloan Ratio of 28.57%, indicating earnings are more likely to be made up of accruals.
Orgenesis Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Orgenesis's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.13(5.44%) Volume: 23,051 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
